Lilly's 7 Acquisitions in 3 Months: Which Will Be the Biggest Game-Changer for the Pharma Giant?
Key takeaways
- LLY NVDA Eli Lilly (NYSE: LLY) spent a lot of 2026 on a shopping spree.
- The purchases cover areas such as sleep medicine, blood cancers, cell therapy, and vaccines.
- In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia.
LLY NVDA Eli Lilly (NYSE: LLY) spent a lot of 2026 on a shopping spree. Riding an obesity drug windfall, the company has announced more than $25 billion in acquisitions across roughly 10 deals this year, with seven of them reported in the last three months alone.
The purchases cover areas such as sleep medicine, blood cancers, cell therapy, and vaccines. In other words, Lilly is diversifying beyond metabolic medicine. But which of the new acquisitions will be the most important for the future of the company?
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »